ADMA Biologics

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The Corporate segment includes general and administrative overhead expenses. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

ADMA Biologics reports robust Q4 results and outlines growth strategies

ADMA Biologics demonstrated strong financial performance and strategic progress in Q4 2022, positioning the company for growth.
The company's focus on operational excellence, product performance, and market acceptance underpins its growth strategy.
Challenges in achieving profitability and market expansion are being addressed through strategic initiatives and operational enhancements.
Opportunities in label expansions, plasma donor targeting, and manufacturing scale-up offer avenues for sustained growth and market differentiation.

ADMA Biologics reports record revenue growth and profitability in Q1

ADMA Biologics demonstrated strong financial performance in Q1 2023, with notable revenue growth and achieving adjusted EBITDA profitability for the first time.
While facing regulatory and operational challenges, the company is strategically positioned for growth, focusing on immune globulin products and patient outcomes.
Management's commitment to innovation, cost efficiencies, and market expansion underscores ADMA's dedication to driving revenue growth and achieving profitability.

ADMA Biologics reports robust Q2 earnings and growth outlook

ADMA Biologics delivered strong financial results, raised revenue guidance, and showcased operational efficiency, positioning the company for sustained growth and market leadership.
The success of ASCENIV and the company's focus on plasma collection underscore ADMA's commitment to patient care, innovation, and social responsibility in the biologics sector.
While facing challenges in a competitive landscape, ADMA has opportunities to expand market reach, increase awareness, and solidify its position as a unique player in the industry.
By balancing financial objectives with social impact goals and emphasizing market differentiation, ADMA can navigate challenges and leverage opportunities for long-term success and stakeholder value.

ADMA Biologics achieves profitability in Q3, poised for growth

ADMA Biologics delivered a strong performance in Q3 2023, achieving profitability for the first time and demonstrating robust revenue growth.
The company's focus on ASCENIV, gross margin improvement, and revenue guidance raise optimism for future prospects and market positioning.
While facing challenges in debt refinancing and patient activation, ADMA Biologics is well-positioned to capitalize on opportunities in product enhancement and market expansion.
Overall, ADMA Biologics' strategic initiatives and financial performance in Q3 indicate a positive trajectory for growth and profitability in the biologics market.

ADMA Biologics achieves positive earnings, focuses on innovation and growth

ADMA Biologics reported a strong financial performance in Q4 2023, achieving positive adjusted net income and cash flow. The company emphasized innovation, growth strategies, and operational efficiencies to drive future success.
While facing challenges in managing profitability and debt, ADMA Biologics is focused on maintaining a strong gross margin profile and developing products targeting specific infectious diseases. The company's commitment to shareholder returns and revenue growth presents opportunities for sustained success.
Overall, ADMA Biologics showcased resilience and strategic planning during the earnings call, with a clear focus on financial stability, innovation, and maximizing shareholder value. The company's positive outlook and growth initiatives position it well for future growth and market competitiveness.

ADMA Biologics reports robust Q1 earnings, eyes sustained growth

ADMA Biologics delivered strong financial performance in Q1 2024, showcasing revenue growth, profitability, and upwardly revised guidance for 2024 and 2025, underlining their growth potential.
The company's focus on innovation, efficiency, and niche markets, along with confidence in long-term growth initiatives, positions them well for sustained value creation and revenue growth beyond 2025.
While facing challenges in operational efficiency, market penetration, and post-2025 revenue growth, ADMA Biologics remains optimistic about growth opportunities and revenue expansion in the coming years.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK, NY / ACCESSWIRE / October 15, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ADMA Biologics, Inc. ("ADMA Biologics, Inc.") (NASDAQ:ADMA) concerning possible violations of federal securities laws. On October 9, 2024, ADMA Biologics disclosed the surprise resignation of its independent outside auditor CohnReznick LLP.

Investors who lost money on ADMA Biologics, Inc. should contact Levi & Korsinsky about an ongoing investigation - ADMA

NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ: ADMA) for potential violations of the federal securities laws. If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/adma-biologics-inc.

ADMA LEGAL NOTICE: ADMA Biologics, Inc. is being Investigated for Securities Fraud after Auditor Resignation; Investors with Losses are Urged to Contact BFA Law (Nasdaq:ADMA)

NEW YORK, NY / ACCESSWIRE / October 14, 2024 / Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ:ADMA) for potential violations of the federal securities laws. If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/adma-biologics-inc.

ADMA INVESTOR UPDATE: ADMA Biologics, Inc. Stock Drops 20% after Auditor Resigns; Contact BFA Law if You Suffered Losses on Your Investment

NEW YORK, NY / ACCESSWIRE / October 14, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ADMA Biologics, Inc. ("ADMA Biologics, Inc.") (NASDAQ:ADMA) concerning possible violations of federal securities laws. On October 9, 2024, ADMA Biologics disclosed the surprise resignation of its independent outside auditor CohnReznick LLP.

ADMA Biologics, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - ADMA

NEW YORK, NY / ACCESSWIRE / October 14, 2024 / Pomerantz LLP is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ:ADMA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA

Shareholders That Lost Money on ADMA Biologics, Inc. (ADMA) Should Contact Levi & Korsinsky About Securities Fraud Investigation - ADMA

NEW YORK CITY, NY / ACCESSWIRE / October 14, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ADMA Biologics Inc ("ADMA Biologics" or "the Company") (NASDAQ:ADMA). Investors who purchased ADMA Biologics securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ADMA.

Bronstein, Gewirtz & Grossman, LLC Is Investigating ADMA Biologics Inc (ADMA) And Encourages Stockholders to Connect

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Is It Worth Investing in Adma Biologics (ADMA) Based on Wall Street's Bullish Views?

ADMA STOCK ALERT: Levi & Korsinsky Notifies ADMA Biologics, Inc. Investors of an Ongoing Investigation

NEW YORK, NY / ACCESSWIRE / October 13, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ADMA Biologics, Inc. ("ADMA Biologics, Inc.") (NASDAQ:ADMA) concerning possible violations of federal securities laws. On October 9, 2024, ADMA Biologics disclosed the surprise resignation of its independent outside auditor CohnReznick LLP.

Levi & Korsinsky Announces an Investigation on Behalf of ADMA Biologics, Inc. (ADMA) Shareholders Who May Have Been Affected by Fraud

NEW YORK, Oct. 13, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ: ADMA) for potential violations of the federal securities laws. If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/adma-biologics-inc.

ADMA SHAREHOLDER ALERT: ADMA Biologics, Inc. is Under Investigation for Securities Fraud after Auditor Resignation and 20% Stock Drop; Investors are Urged to Contact BFA Law (Nasdaq:ADMA)

NEW YORK, NY / ACCESSWIRE / October 12, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ADMA Biologics, Inc. ("ADMA Biologics, Inc.") (NASDAQ:ADMA) concerning possible violations of federal securities laws. On October 9, 2024, ADMA Biologics disclosed the surprise resignation of its independent outside auditor CohnReznick LLP.

Shareholder Rights Advocates at Levi & Korsinsky Investigate ADMA Biologics, Inc. (ADMA) Regarding Possible Securities Fraud Violations

NEW YORK, NY / ACCESSWIRE / October 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ADMA Biologics, Inc. ("ADMA Biologics, Inc.") (NASDAQ:ADMA) concerning possible violations of federal securities laws. On October 9, 2024, ADMA Biologics disclosed the surprise resignation of its independent outside auditor CohnReznick LLP.

ADMA ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your ADMA Biologics, Inc. investment

NEW YORK, NY / ACCESSWIRE / October 11, 2024 / Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ:ADMA) for potential violations of the federal securities laws. If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/adma-biologics-inc.

ADMA LEGAL NEWS: ADMA Biologics, Inc. Investors with Losses are Urged to Contact BFA Law about Pending Securities Fraud Investigation (Nasdaq:ADMA)

Lost Money on ADMA Biologics, Inc. (ADMA)? Contact Levi & Korsinsky Regarding an Ongoing Investigation

SAN DIEGO, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP is investigating whether ADMA Biologics, Inc. (NASDAQ: ADMA) or any of its executive officers or others violated securities laws by misrepresenting or failing to timely disclose material, adverse information to investors. The investigation focuses on investors' losses and whether they may be recovered under federal securities laws.

Johnson Fistel Begins Investigation into ADMA Biologics, Inc. Following a Significant Drop in the Company's Stock

BOSTON, MA / ACCESSWIRE / October 11, 2024 / Block & Leviton is investigating ADMA Biologics, Inc. (Nasdaq:ADMA) for potential securities law violations. Investors who have lost money in their ADMA Biologics investment should contact the firm to learn more about how they might recover those losses.

ADMA Biologics ALERT: Securities Fraud Investigation by Block & Leviton Could Allow Investors to Recover Losses

NEW YORK, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ: ADMA) for potential violations of the federal securities laws. If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/adma-biologics-inc.

ADMA FRAUD ALERT: BFA Law is Investigating ADMA Biologics, Inc. for Securities Fraud after Stock Drops 20%; Investors with Losses are Urged to Contact the Firm (Nasdaq:ADMA)

Atour Lifestyle Holdings Ltd

Corcept Therapeutics

360 Finance Inc - ADR

Vertiv Holdings Co

Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are ATAT, VRT, CORT, QFIN, ADMA.

5 Stocks With Recent Price Strength Amid October Volatility

Investors can contact the law firm at no cost to learn more about recovering their losses

ADMA Biologics, Inc. Investors: Company Investigated by the Portnoy Law Firm

NEW YORK, NY / ACCESSWIRE / October 10, 2024 / Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ:ADMA) for potential violations of the federal securities laws. If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/adma-biologics-inc.

ADMA STOCK DROP ALERT: ADMA Biologics, Inc. Stock Drops over 20%; BFA Law Initiates Securities Fraud Investigation and Urges Investors with Losses to Contact the Firm (Nasdaq:ADMA)

Block & Leviton is investigating ADMA Biologics for potential securities law violations. Investors who have lost money in ADMA should contact the firm.

ADMA Biologics Investors Who Have Lost Money Should Contact Block & Leviton to Find Out How They Might Recover Money Through The Firm's Investigation

The latest trading day saw Adma Biologics (ADMA) settling at $20.33, representing a -1.91% change from its previous close.

Adma Biologics (ADMA) Stock Dips While Market Gains: Key Facts

Lumen Technologies

Powell Industries

Vistra Energy

If you're like most investors — you assume AI giant Nvidia is the best stock of the year. But 2024's major champ isn't even in the S&P 500.

The Real Best Stock Of The Year Isn't In The S&P 500 Yet

Eagle Bancorp Montana

Talos Energy Inc

Targa Resources

Vertex, Inc.

ADMA, VERX, TRGP, EBMT and TALO have been added to the Zacks Rank #1 (Strong Buy) List on October 7, 2024.

News for ADMA Biologics Stock (ADMA)